Longeveron Showcases Innovations at Emerging Growth Event

Longeveron Set to Present at the Emerging Growth Virtual Conference

MIAMI -- Longeveron Inc. (NASDAQ: LGVN), a pioneering clinical stage regenerative medicine biotechnology firm, is gearing up for its participation in the Emerging Growth Virtual Conference. This event is scheduled for December 4-5, 2024, and represents a significant opportunity for the company to showcase its groundbreaking innovations in cellular therapies aimed at life-threatening and chronic aging-related conditions.

Presentation Details and What to Expect

Longeveron's presentation will take place on December 5, 2024, from 12:00 to 12:30 p.m. ET. Industry professionals and interested parties can access the presentation through the company's dedicated “Events and Presentations” section on its website. Attendees will have the opportunity to engage with the presentation and ask questions either in advance or during the live event.

Webcast Information

After the conference, a replay of the webcast will be available on the Longeveron website for 180 days, allowing shareholders and stakeholders to access the content at their convenience. This reaffirms Longeveron’s commitment to transparency and accessibility for its investors and the broader community.

About Longeveron Inc.

Longeveron specializes in developing regenerative medicines addressing unmet medical needs through innovative biotechnology. Its flagship product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from healthy adult donors' bone marrow. This unique therapy showcases a variety of potential mechanisms, demonstrating properties that are pro-vascular, anti-inflammatory, and instrumental in tissue repair and healing.

Pipeline and Regulatory Designations

The company is currently focusing on three main indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and age-related frailty. Lomecel-B™ has garnered extensive recognition from regulatory agencies, receiving key FDA designations for its developmental programs, including Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) status, which highlight its potential to transform treatment in these critical areas.

Company Vision and Future Directions

Longeveron aims to leverage its capabilities to further advance its product offerings and expand its clinical trials, thereby improving the lives of patients with chronic conditions. With its cutting-edge research and development strategies, the company is well-positioned to make significant advancements in the biotechnology sector.

Contact Information

For any inquiries or additional information regarding investor relations, please reach out to Derek Cole at Investor Relations Advisory Solutions via email at derek.cole@iradvisory.com. The company encourages open communication with its stakeholders as they continue on their path of growth and innovation.

Frequently Asked Questions

What is Longeveron Inc. known for?

Longeveron Inc. is known for developing innovative cellular therapies for life-threatening and chronic aging-related conditions.

When will Longeveron present at the Emerging Growth Conference?

Longeveron will present on December 5, 2024, from 12:00 to 12:30 p.m. ET.

How can I access the conference presentation?

The conference presentation can be accessed through the “Events and Presentations” section on Longeveron’s website.

What is Lomecel-B™?

Lomecel-B™ is an allogeneic medicinal signaling cell therapy designed to address various medical needs, including hypoplastic left heart syndrome and Alzheimer’s disease.

What regulatory designations has Longeveron received?

Longeveron has received several FDA designations, including Orphan Drug, Fast Track, and RMAT designations for Lomecel-B™.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.